A phase 1 trial of human telomerase reverse transcriptase (hTERT) vaccination combined with therapeutic strategies to control immune-suppressor mechanisms.

"clinical response could be improved by combination with anti-pd1 checkpoint inhibition to address the emergence of an exhausted t cell population 1 http://www syfpeithi de/ 2 available at: https://github com/kordastilab/cytoclustr author contributions oe js ff sk je and dl conceived and supervised the study and wrote the manuscript."

"Conflict of interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."

"The trial was funded by the Candles Charity [Grant Number 1125834] and sponsored by King’s Health Partners. The authors acknowledge additional financial support from the UK Department of Health and Cancer Research UK via Experimental Cancer Medicine Centre grants to King’s Health Partners and the University of Cambridge/Addenbrooke’s Hospital. These centres also hold National Institute for Health Research Biomedical Research Centre (BRC) awards. In Cambridge [Grant Number #BRC-1215-20014] also supports the Cambridge Clinical Research Centre where study participants were seen. We acknowledge the BRC Immune Monitoring Core Facility team at Guy’s and St Thomas’ NHS Foundation Trust [Grant Number IS-BRC-1215-20006] for flow cytometry facilities and assistance, and the Cancer Research UK King’s Health Partners Centre at King’s College London [Grant Number C604/A25135]."